A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting
Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal
impairment. This study is considered research and is voluntary.
Phase:
Phase 3
Details
Lead Sponsor:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)